---
title: 'Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive
  analysis of cancer clinical trials leading to FDA and EMA approvals between 2020
  and 2022'
date: '2025-01-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39754982/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250105170515&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Ethnic homogenous participants and eligibility criteria
  that favor majority groups limit the applicability of findings in diverse populations,
  leading to inadequate patient management. While United States guidelines encourage
  inclusivity, similar recommendations are lacking in Europe. Thus European regulatory
  authorities, research organizations, and patient advocates should establish guidelines
  to improve ethnic diversity in cancer clinical trials, aligning research practices
  ...'
disable_comments: true
---
CONCLUSIONS: Ethnic homogenous participants and eligibility criteria that favor majority groups limit the applicability of findings in diverse populations, leading to inadequate patient management. While United States guidelines encourage inclusivity, similar recommendations are lacking in Europe. Thus European regulatory authorities, research organizations, and patient advocates should establish guidelines to improve ethnic diversity in cancer clinical trials, aligning research practices ...